Could a gut bacteria pill help ARDS patients breathe easier?
NCT ID NCT07646028
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests R-3750, a live biotherapeutic product, in 20 adults with late-stage acute respiratory distress syndrome (ARDS). The main goal is to see if it is safe and tolerable, while also checking for signs of improved lung function and less need for a ventilator. Participants take the drug daily by mouth or through a feeding tube.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- R-3750 (a live biotherapeutic product given as capsules or through a feeding tube)
- What this could lead to
- If safe and effective, R-3750 could offer a new way to reduce ventilator dependence and improve lung function in late-stage ARDS patients.
- What could go wrong
- This is a very early Phase 1 trial with only 20 participants, so safety and effectiveness are not yet proven. The treatment may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Lung-Opening maneuver change a key injury marker in ARDS?
- Could simply sitting up ease breathing in severe lung failure?
- Could lung fluid proteins reveal a new way to track severe lung injury?
- Could a spirometer test guide breathing support in respiratory failure?
- Which ventilator setting saves more lungs? a Head-to-Head test
- Can a single antibody turn down the immune storm in ARDS?